Tarsus bets $450M on Alkeus’ Stargardt drug
To broaden its ophthalmology portfolio, Tarsus Pharmaceuticals is dishing out $450 million upfront to acquire Phase 3 biotech Alkeus Pharmaceuticals, the companies said Thursday morning. It's the latest signal that small- ...
Tarsus Pharmaceuticals CEO Bobby Azamian speaks at Endpoints' #JPM26 event (Brian Benton Photography) August 6, 2026 08:57 AM EDT Deals Tarsus bets $450M on Alkeus’ Stargardt drug Kyle LaHucik Biotech Correspondent To broaden its ophthalmology portfolio, Tarsus Pharmaceuticals is dishing out $450 million upfront to acquire Phase 3 biotech Alkeus Pharmaceuticals, the companies Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that